The drug discovery technology producer received $50m from strategic partner Bayer in the round, which valued it at about $1.2bn post-money.
Pharmaceutical and agricultural product manufacturer Bayer invested $50m to lead a $239m series D round for US-based drug discovery technology provider Recursion yesterday through its Leaps by Bayer subsidiary.
Fellow new investors Casdin Capital, Catalio Capital Management, Laurion Capital Management and Samsara BioCapital also took part in the round, which valued Recursion just below $1bn pre-money, a person with knowledge of the matter told The Information.
The round was filled out by existing backers including Intermountain Ventures, care provider Intermountain…
